ArticleOncology letters2026
Development and evaluation of clinical models based on ultrasound, serum CA153 and molecular subtype in predicting the efficacy of neoadjuvant chemotherapy in breast cancer.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is a threat to health, and reliable predictors for neoadjuvant chemotherapy (NAC) efficacy remain limited. The aim of the present study was to develop a clinical model that combines ultrasonography with clinical and pathological characteristics to predict the effectiveness of NAC in patients with breast cancer prior to surgery. The present retrospective study included patients with pathologically confirmed primary breast cancer who underwent NAC followed by surgery based on predefined inclusion and exclusion criteria. Patients were randomly allocated to a test and a validation set in a 7:3 ratio. Clinical data, comprehensive pathological reports and ultrasound imaging features were collected from the Hospital Information System of Hubei Cancer Hospital (Wuhan, China). Univariate and multivariate logistic regression analyses were conducted to identify independent predictive factors, with significance set at a bilateral P<0.05. The receiver operating characteristic curve was used to assess the performance of the model. The present study included 323 female patients with breast cancer. Univariate analysis indicated significant differences in tumor diameter changes, mass margin and posterior echo patterns (classified as shadow, enhancement or no posterior features), change in serum carbohydrate antigen 153 (CA153) levels, clinical N stage (classified as cN0-cN3), hormone receptor expression, Ki-67 levels and molecular type between the pathological complete response (pCR) and pathological incomplete response (non-pCR) group. Multivariate analysis identified margin, molecular subtype, changes in tumor diameter and serum CA153 levels as significant predictors included in the final model (P<0.05). Furthermore, the present study model was validated in the validation set. The area under the curve for the predictive model in test set was 0.823 (95% confidence interval, 0.765-0.881), while in the validation set, it was 0.884 (95% confidence interval, 0.816-0.953). The integrated model, which incorporated ultrasound, serum CA153 levels and molecular subtypes, demonstrated notable potential for preoperative assessment of NAC efficacy in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.